Back to search
FDAFDA · Food and drugs·Recall number D-0659-2024

AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01

Published September 25, 2024 · Recall initiated: August 24, 2024

Summary

FDA records drug Class III recall D-0659-2024, published September 25, 2024 and initiated August 24, 2024. Recalling firm: Rubicon Research Private Limited; Status: Ongoing; Reported quantity: 3,984 bottles; Lot: Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Discoloration

What to do

Voluntary: Firm initiated · Letter

Get an email if ACETAZOLAMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ACETAZOLAMIDE
Manufacturer
Rubicon Research Private Limited
Distributor
Nationwide in the US
UPC
0372888047010
Lot
Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01
Risk classification
Class III
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01 recalled?

Yes. FDA published recall D-0659-2024 on September 25, 2024. Reported hazard: Discoloration

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ACETAZOLAMIDE. UPC: 0372888047010.